Fludarabine

Type 1 Papillary Renal Cell Carcinoma

Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Type 1 Papillary Renal Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Crizotinib National Cancer Institute (NCI)	Phase 2	B
Irinotecan National Cancer Institute (NCI)	Phase 2	B
Tas-102 National Cancer Institute (NCI)	Phase 2	B
Tivantinib National Cancer Institute (NCI)	Phase 2	B
(+)-VINCRISTINE National Cancer Institute (NCI)	Phase 2	B

View all 15 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Fanconi anemiaDormant

BBB

Indicative ·

76 / 100

Recurrent Adult Diffuse Large Cell LymphomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.